• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Evaluation of novel second-generation RSV and influenza rapid tests at the point of care

tetano

Editor, Senior Moderator
Diagn Microbiol Infect Dis. 2014 Dec 3. pii: S0732-8893(14)00484-2. doi: 10.1016/j.diagmicrobio.2014.11.013. [Epub ahead of print]
[h=1]Evaluation of novel second-generation RSV and influenza rapid tests at the point of care.[/h] Tuttle R[SUP]1[/SUP], Weick A[SUP]2[/SUP], Schwarz WS[SUP]3[/SUP], Chen X[SUP]4[/SUP], Obermeier P[SUP]5[/SUP], Seeber L[SUP]6[/SUP], Tief F[SUP]7[/SUP], Muehlhans S[SUP]8[/SUP], Karsch K[SUP]9[/SUP], Peiser C[SUP]10[/SUP], Duwe S[SUP]11[/SUP], Schweiger B[SUP]12[/SUP], Rath B[SUP]13[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Acute respiratory infections represent common pediatric emergencies. Infection control warrants immediate and accurate diagnoses. In the past, first-generation respiratory syncytial virus (RSV) rapid tests (strip tests) have shown suboptimal sensitivities. In 2013, the Food and Drug Administration licensed a second-generation RSV rapid test providing user-independent readouts (SOFIA?-RSV) using automated fluorescence assay technology known to yield superior results with influenza rapid testing. We are reporting the first point-of-care evaluation of the SOFIA?-RSV rapid test. In the Charit? Influenza-Like Disease Cohort, 686 nasopharyngeal samples were tested in parallel with SOFIA?-RSV and SOFIA?-Influenza A+B. Compared to real-time PCR, SOFIA?-RSV sensitivities/specificities were 78.6%/93.9%, respectively (SOFIA?-Influenza A: 80.6%/99.3%). Performance was greatest in patients below 2years of age with a test sensitivity of 81.8%. RSV sensitivities were highest (85%) in the first 2days of illness and with nasopharyngeal compared to nasal swabs (P=0.055, McNemar's test). Second-generation RSV and influenza rapid testing provides highly accurate results facilitating timely patient cohortation and management.
Copyright ? 2014 Elsevier Inc. All rights reserved.


[h=4]KEYWORDS:[/h] Influenza-like illness; Minimally-invasive testing; Point-of-care diagnostics; Rapid testing; Respiratory syncytial virus

PMID: 25583129 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25583129
 
Back
Top Bottom